Login / Signup

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.

Michael Markus BonelliDaniel MrakThomas PerkmannHelmuth HaslacherDaniel Aletaha
Published in: Annals of the rheumatic diseases (2021)
Keyphrases
  • immune response
  • sars cov
  • newly diagnosed
  • ejection fraction
  • toll like receptor
  • patient reported outcomes
  • respiratory syndrome coronavirus
  • hodgkin lymphoma